Deep Brain Stimulation for Severe Anorexia Nervosa
The somatic complications as well as the suicidal risk make Anorexia Nervosa (AN) the psychiatric disease with the highest mortality rate: the standardized mortality ratio is higher than 4 and 1 in 5 patients with AN who dies has committed suicide. Approximately 20% of patients suffering from AN evolves into a chronic
| Condition(s) | Anorexia Nervosa |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The somatic complications as well as the suicidal risk make Anorexia Nervosa (AN) the psychiatric disease with the highest mortality rate: the standardized mortality ratio is higher than 4 and 1 in 5 patients with AN who dies has committed suicide. Approximately 20% of patients suffering from AN evolves into a chronic form without prolonged remission. These patients are at high risk of serious complications (somatic and psychiatric). The peak incidence of AN lies between 15 and 19 years: patients suffering from severe and resistant AN are therefore mostly young people. At present, there is no treatment for severe and resistant AN. New insights in AN pathophysiology revealed that AN patients develop a kind of "addiction" to thinness which contributes to weight loss despite negative conseque |
| Who can participate | Inclusion Criteria: 1. Diagnosis of Anorexia nervosa according to DSM V criteria. 2. Age 18 to 65 years. 3. Chronic, treatment-resistant anorexia nervosa, defined as: * Anorexia nervosa evolving for at least 7 years. * Inability to maintain a BMI ≥ 17kg/m² for 2 months following hospitalization in a center specialized for the management of patients suffering from eating disorders according to the criteria of the French Federation of Anorexia and Bulimia nervosa and the Directorate General of Care Provision (Direction Générale de l'Offre de Soins - DGOS, in French). Failure of at least 2 hospitalizations in a specialized center during the history of the disease. * Inability to maintain a BMI ≥ 17kg/m² for more than 3 consecutive months during an outpatient treatment conducted by a team spec |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier St Anne |
| Locations | Paris, France |
| Start date | 2022-04-14 |
| NCT ID | NCT05245643 |
| Official listing | https://clinicaltrials.gov/study/NCT05245643 |